Abstract
Objective
To assess the response to antithymocyte globulin based immunosuppressive therapy (IST) in pediatric patients with idiopathic aplastic anemia.
Methods
Thirty patients (19 boys and 11 girls) with aplastic anemia received antithymocyte globulin and cyclosporine. Twenty-two patients had severe and 8 had very severe aplastic anemia.
Results
Mean age of the patients was 9.19 ± 2.56 y. Three patients died within 1 mo of therapy, two due to sepsis and one due to intracranial hemorrhage. Twenty-seven patients were analyzed for response to therapy. Eight patients (29.7%) responded at 3 mo: 3 complete response (CR) and 5 partial response (PR). Six mo after the therapy, overall response (OR) was seen in 9/27 (33.3%), with one more patient in no response group achieving partial response. At 1 year, patients in CR maintained their status and 1 patient in PR group relapsed. He again achieved partial response with repeat course of ATG. Responders had significantly shorter duration of illness and higher absolute neutrophil count as compared to non responders to IST. None of the patients developed acute leukemia in the follow up.
Conclusions
The treatment of aplastic anemia in pediatric patients is a challenging task. One third of the patients achieved overall response which included both complete and partial response.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Young NS. Acquired aplastic anemia. Annals Int Med. 2002;136:534–46.
Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2509–19.
Rosenfeld SE, Kimball J, Vining D, Young NS. Intensive immunosuppression with Antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood. 1995;85:3058–65.
International Agranulocytosis and Aplastic Anaemia study. Incidence of aplastic anemia: relevance of diagnostic criteria. Blood. 1987;70:1718–21.
Camitta BM, Rappeport JM, Parkman R, Nathan DG. Selection of patients for bone marrow transplantation in severe aplastic anemia. Blood. 1975;45:355–63.
Bacigalupo A, Hows JM, Gluckman E, et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): a report of the EBMT SAA Working Party. Br J Haematol. 1988;70:177–82.
Marsh JCW, Ball SE, Darbyshire P, et al. Guidelines for the diagnosis and management of acquired aplastic anemia. Br J Haematol. 2003;123:782–801.
Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. German aplastic anemia study group. Blood. 2003;101:1236–42.
Frickhofen N, Rosenfeld SJ. Immunosuppressive therapy of aplastic anemia with antithymocyte globulin and cyclosporine. Semin Hematol. 2000;37:56–68.
Guinan EC. Acquired aplastic anemia in childhood. Haematol Oncol Clin North Am. 2009;23:171–91.
Marwaha RK, Bansal D, Trehan A, Varma N. Androgens in childhood acquired aplastic anemia in Chandigarh, India. Trop Doc. 2004;34:149–52.
Rai M, Singh VP, Shukla J, et al. Low dose cyclosporine- a therapy in severe aplastic anemia. J Assoc Physicians India. 2001;49:966–99.
Chandra J, Naithani R, Ravi R, et al. Antithymocyte globulin and cyclosporine in children with acquired aplastic anemia. Indian J Pediatr. 2008;75:229–33.
George B, Mathews V, Viswabandya A, Lakshmi KM, Srivastava A, Chandy M. Allogeneic hematopoetic stem cell transplantation is superior to immunosuppressive therapy in Indian children with aplastic anemia-a single center analysis of 100 patients. Pediatr Hematol Oncol. 2010;27:122–31.
Bacigalupo A, Bruno B, Saracco P. Anti thymocyte globulin, cyclosporine, prednisolone and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients: European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO). Blood. 2000;95:1931–4.
Di Bona E, Rodeghiero F, Bruno BA, et al. Rabbit antithymocyte globulin (r-ATG) plus cyclosporine and granulocyte colony stimulating factor is an effective treatment for aplastic anemia unresponsive to a first course of intensive immunosuppressive therapy. Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Br J Haematol. 1999;107:330–4.
Kamio T, Ito E, Ohara A, Kosaka Y, et al. Relapse of aplastic anemia in children after immunosuppressive therapy: A report from the Japan Childhood aplastic anemia study group. Haematologica. 2011;96:814–9.
Gupta V, Gordon-Smith EC, Cook G, et al. A third course of anti-thymocyte globulin in aplastic anemia is only beneficial in previous responders. Br J Haematol. 2005;129:110–7.
Rosenfeld S, Follman D, Nunez O, Young NS. Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA. 2003;289:1130–5.
Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000;37:91–101.
Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myeloid leukemia as a late complication in children with acquired aplastic anemia. Blood. 1997;90:1009–13.
Kojima S, Hibi S, Kosaka Y, et al. Immunosuppressive therapy using Antithymocyte globulin, cyclosporine, and danazol with or without human granulocyte colony-stimulating factor in children with acquired aplastic anemia. Blood. 2000;96:2049–54.
Conflict of Interest
None.
Role of Funding Source
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gupta, V., Kumar, A., Tilak, V. et al. Immunosuppressive Therapy in Aplastic Anemia. Indian J Pediatr 79, 1587–1591 (2012). https://doi.org/10.1007/s12098-012-0691-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-012-0691-2